Roche View On Biogenerics: “They Will Come,” But Process Won’t Be Simple
Executive Summary
Roche's ongoing supply agreement with Centocor for the thrombolytic Retavase illustrates the practical obstacles to commercialization of generic biologics, Roche Global Pharmaceuticals Head William Burns told a securities analysts briefing July 23 in Zurich
You may also be interested in...
J&J Puts A Cork In Eprex Problem: Teflon-Coated Stopper May Solve PRCA
Johnson & Johnson believes that the incidence of pure red cell aplasia seen with the overseas epoetin brand Eprex was most likely caused by leaching from rubber stoppers used in vials of the product
J&J Puts A Cork In Eprex Problem: Teflon-Coated Stopper May Solve PRCA
Johnson & Johnson believes that the incidence of pure red cell aplasia seen with the overseas epoetin brand Eprex was most likely caused by leaching from rubber stoppers used in vials of the product
Roche Will Challenge Amgen In U.S. EPO Market; Oncology Business Growing
Roche expects to enter the U.S. EPO market with the continuous erythropoetin receptor activator R-744, Global Pharmaceuticals Head William Burns told securities analysts during a July 23 meeting in Zurich